Geron corporation stock forecast

Small-cap biotech Geron (NSDQ: GERN) has been on Wall Street’s radar lately, as bullish sentiment over the company waxes and wanes. The stock enjoyed a huge spike in mid-February, although it has since cooled off. Problem is, Geron is a clinical stage developer of cancer drugs. Geron Corporation (GERN) Analyst Ratings, Estimates ... See Geron Corporation (GERN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. Geron Corporation (GERN) Stock Price, Quote, History ... Find the latest Geron Corporation (GERN) stock quote, history, news and other vital information to help you with your stock trading and investing. Geron Corporation (GERN) Stock Analysis & News | Seeking Alpha Get breaking news and analysis on Geron Corporation (GERN) stock, price quote and chart, trading and investing tools.

GERN Stock Quote of Geron Corp - InvestorPlace

Higher open puts stock market on track to halt multisession skid as traders absorb data, Fed hike MarketWatch. 08:04 AM ET. Geron's stock plunges to pace all premarket losers after Janssen terminates CLA MarketWatch. 06:43 AM ET. Geron's stock plunges 65% premarket after collaboration deal with Janssen is terminated MarketWatch. Thursday, July Geron Corporation - GERN - Stock Price Today - Zacks View Geron Corporation GERN investment & stock information. Get the latest Geron Corporation GERN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Stock Analysis for Geron Corporation (GERN) Geron Corporation lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -6.76% during the next 3 months and, with 90% probability hold a price between $1.13 and $1.39 at the end of this period. Does Geron Corporation Stock Belong in Your Portfolio in ...

GERN - Geron Corporation Stock Prediction and Analysis ...

The historical data and Price History for Geron Corp (GERN) with Intraday, Daily, Weekly, Monthly, and Quarterly data available for download. Indexes Soybean Indexes Wheat Indexes Scrap Metal Indexes Retail Gas Indexes Retail Diesel Indexes Crude Oil Indexes Yield Forecast Indexes. The Corporation Actions tab shows stock splits

View Geron Corporation GERN investment & stock information. Get the latest Geron Corporation GERN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Social media updates, opinions, and reactions on Geron Corporation (GERN) aggregated in real time from around the web on NASDAQ.com Geron Corporation Price (GERN) Forecast with Price Charts Geron Corporation Forecast, Short-Term " GERN" Stock Price Prognosis for Next Days Walletinvestor.com GERN Forecast, Long-Term Price Predictions for Next Months and Year: 2020, 2021 Imetelstat | Myelofibrosis | Myelodysplastic Syndrome | Geron Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Geron Corp., GERN Quick Chart - (NAS) GERN, Geron Corp ... Higher open puts stock market on track to halt multisession skid as traders absorb data, Fed hike MarketWatch. 08:04 AM ET. Geron's stock plunges to pace all premarket losers after Janssen terminates CLA MarketWatch. 06:43 AM ET. Geron's stock plunges 65% premarket after collaboration deal with Janssen is terminated MarketWatch. Thursday, July

GERN Stock Quote of Geron Corp - InvestorPlace

Mar 23, 2020 · Analyst recommendations provided by FactSet shows that the consensus forecast for Geron Corporation (GERN) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated Geron Corporation - Investors - FAQs On October 1, 2013, Geron closed the transaction to divest its human embryonic stem cell assets and autologous cellular immunotherapy program to Asterias Biotherapeutics, Inc. In connection with the divestiture, Geron received 6,537,779 shares of Asterias Series A common stock. GERN - Geron Corporation Stock Prediction and Analysis ... Dec 29, 2014 · The stock analysis for Geron Corporation (GERN) is based on the analysis and stock picks of our best trading systems. By aggregating the opinions and predictions of our best trading systems (trading bots), we come up with a general prediction.

Here is a breakdown of the Geron Corporation (GERN) stock ... Mar 23, 2020 · Analyst recommendations provided by FactSet shows that the consensus forecast for Geron Corporation (GERN) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated Geron Corporation - Investors - FAQs On October 1, 2013, Geron closed the transaction to divest its human embryonic stem cell assets and autologous cellular immunotherapy program to Asterias Biotherapeutics, Inc. In connection with the divestiture, Geron received 6,537,779 shares of Asterias Series A common stock. GERN - Geron Corporation Stock Prediction and Analysis ... Dec 29, 2014 · The stock analysis for Geron Corporation (GERN) is based on the analysis and stock picks of our best trading systems. By aggregating the opinions and predictions of our best trading systems (trading bots), we come up with a general prediction.